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Quality of life has become an important outcome of interest
Methods in clinical medicine and has ''grown from a cottage industry Information concerning the categorization and review of to a large academic enterprise'' [1] . Nevertheless, controversy HRQL instruments was obtained from a literature search using and criticism have surrounded its definition, scope, and applicathe National Library of Medicine Bibliographic Retrieval Serbility [1, 2] . The purpose of this article is to review the types vices, Inc., or MEDLINE. Only English-language review artiof quality-of-life instruments developed to date, the methods cles found with the key words ''quality of life'' or ''healthused to evaluate them, and their applications to HIV disease related quality of life'' were considered. through July 1996.
Journal articles concerning HRQL for HIV-infected patients In the most general terms, quality of life extends beyond were obtained through a MEDLINE search using combinations health. It may include satisfaction with one's geographic locaof the key words ''quality of life,'' ''health-related quality of tion, access to education, or level of income. In a clinical life,'' ''health status indicators,'' ''disability,'' and ''human setting, the definition is limited to those aspects of life directly immunodeficiency virus,'' ''acquired immunodeficiency synaffected by the health state or health care, extends beyond drome,'' or ''communicable diseases.'' Only English-language conventional assessments of health, and is often referred to as articles published before July 1996 were considered for review. health-related quality of life (HRQL) [3] . HRQL is the focus
The bibliographies of the articles discovered in this way were of this review, and this term will be used throughout the article. also used as a source of articles for review. The increasing number of HRQL instruments being developed reflects a lack of consensus for a single instrument that adequately measures HRQL with enough sensitivity to detect Categorization of HRQL Instruments significant changes for all diseases. HRQL instruments have
The most distilled categorization of HRQL instruments puts been used in several different ways: to compare treatment opthem into two realms, generic and specific [3] . Generic instrutions in clinical trials, to assess outcome measures in health ments are designed to incorporate multiple dimensions of services or evaluation research, to assist in cost-utility analyses, HRQL, such as the physical, social, and emotional dimensions. to screen and monitor individual patient care, to survey populaBecause of their breadth, generic instruments can be used to tions for perceived health problems, and to conduct medical compare HRQL among different diseases or populations. Geaudits [4] . Although some of these uses are viewed skeptically, neric instruments can further be broken down into ''health their utility in clinical trials to identify optimal treatment regiprofiles'' and ''utility-based'' instruments [3] . mens with quantitative certainty is difficult to deny when the Health profiles are batteries of questions directed to the paappropriate instrument is used.
tient, covering multiple aspects of HRQL separately. They vary with respect to their emphasis, the number of questions, and the amount of time it takes to complete them. The scales em-comes Study General Health Survey, the Nottingham Health Currently, a universal gold standard does not exist, but if a longer version of a questionnaire has already been established Profile, and the Health Assessment Questionnaire. Although these instruments may be very useful in comparing HRQL as valid for a disease, a shorter version can be validated against the longer one [3] . When no gold standard exists for explicit between some diseases, their utility for other diseases may vary. For example, the VF-14, a questionnaire designed to comparison, one could establish validity implicitly by asking patients, doctors, nurses, social scientists, or allied health care measure functional impairment specifically caused by cataracts, was able to detect impairment of HRQL that the Sickness workers if the method of measurement seems to cover the intended aspects of HRQL (face validity) comprehensively Impact Profile was not, when the scales were compared directly with each other [5] .
(content validity) [4] . Construct validity is based on the comparison of an instrument's performance to a theoretical conUtility-based instruments evolved from economic theory of choice and decision analysis and are used when a decision struct assumed by the investigator to be true [3] . Alternatively, validity can be established as in the case of the Health Assessmust be made between alternatives with limited information available [6] . The most widely used scales are those that meament Questionnaire, which was originally used to measure HRQL for patients with rheumatoid arthritis (nurse assessors sure HRQL by a single numerical value on a continuum from death (0.0) to complete health (1.0). This number indiscrimiwere sent to patients' homes to confirm their responses to functional disability questions) [10] . nately includes all aspects of a patient's HRQL. Examples of instruments used for obtaining this rating include the Standard Measuring responsiveness, or the ability of an instrument to detect significant changes in HRQL quantitatively by a signifiGamble and Time Trade-Off analyses.
The Standard Gamble asks patients to ''gamble'' (for examcant change in score, also becomes difficult when there is no established standard. It may be that the HRQL instrument must ple, with therapeutic options) between their own present health state and complete health or immediate death. The Time Tradebe compared to other health status measures or to the patient's or the doctor's perception of a change in health status [4] . Off approach involves how much time in full health subjects would trade for their own present health state [7] . The QualityInterpretability is the ability to translate a significant change or difference in HRQL score to a change in health status. For Adjusted Time Without Symptoms of Disease and Toxicity of Treatment (Q-TWiST) instrument partitions HRQL choices and example, does a change in score mean that the patient is much better or just moderately better, and how seriously does that examines the partitions over time. Specifically, it measures quality-weighted survival time by summing weighted scores impact on the patient's daily life? through well-defined health states [8] . The Q-TWiST and other utility-based instruments are most useful when there is a cost-HRQL Studies for Patients with HIV Disease utility comparison of treatments required. These instruments generally place less emphasis on the individual patient than on HRQL instruments are most applicable to chronic diseases. At the start of the HRQL movement, the majority of studies populations of patients, and they do not distinguish the effects of a disease or treatment on particular aspects of HRQL [3] .
focused on pulmonary, cardiac, and rheumatological diseases. In the last 7 -8 years, there has been an explosion of HRQL Specific instruments measure HRQL for a specific disease (Living with Asthma Questionnaire), a particular aspect of pawork done with HIV disease. Although it is not the only infectious disease studied, HIV infection is the most extensively tient care (Hospice Quality-of-Life Index), a particular dimension of HRQL (Profile of Mood States), or a particular populastudied. The HIV-infected population presents a special challenge to those measuring HRQL because it is generally younger tion such as geriatric or pediatric patients. Specific measures, therefore, address health-related issues of special interest to the than other populations and often belongs to ''marginalized'' communities (homosexual males, intravenous drug abusers, appropriate patient. Because of their targeted inquiry, specific instruments are not used to compare HRQL among diseases. prisoners) [11] . The utility and value of the studies published are often difficult to interpret: one must look at the measure being used, whether it represents an observed or self-reported Ideal HRQL Instruments HRQL measurement, whether the measure is utility based or is a psychometric health scale, and whether the measure has Instruments used to evaluate HRQL should possess the attributes of reproducibility, responsiveness, validity, and interpretbeen validated. Initial studies incorporated mostly functional scales in cliniability [3, 4] . Reproducibility or reliability means that the instrument elicits similar scores on repeated testing at times when cal trials but did not include formal validation of these scales. The Karnofsky Performance Status (KPS) score, a physician-HRQL is not expected to change. If several interviewers are administering the questionnaire, interrater reliability should rated functional scale, was used in a double-blind, placebocontrolled trial to determine the efficacy of administering 250 also be established [9] .
The four measures of validity are sensitivity, specificity, and mg of zidovudine (AZT) every 4 hours to patients with AIDS and AIDS-related complex (ARC) over a 24-week period (tapositive and negative predictive values. If a ''gold standard'' exists, an instrument can be evaluated against that standard. ble 1) [12] .
/ 9c43$$ja26 11-24-97 20:09:05 cida UC: CID [19] Zidovudine provided .9 mo of disease-free survival at a moderate cost to HRQL at 1 y. HRQL zidovudine vs. placebo) for both groups became similar after that, presumably secondary to disease progression in the placebo group. Early symptomatic HIV disease (high-dose Q-TWiST [20] Treatment provided more Q-TWiST in an 18-mo period if HRQL after disease progression is zidovudine vs. placebo) considered 10% -20% worse than HRQL after a severe symptomatic event. Asymptomatic HIV/ patients (low-dose Q-TWiST [21] Reduction in HRQL secondary to severe side effects of zidovudine nearly equaled the increase in zidovudine vs. placebo) HRQL associated with delay in disease progression. AIDS patients receiving prophylaxis with Q-TWiST, KPS [26] Both symptomatic patients without a diagnosis of AIDS and AIDS patients showed significant and AIDS patients drops in HRQL over a 12-mo period, especially in role functioning and symptoms. Symptomatic HIV/ and AIDS patients also showed decline in ability to work as many hours as before. Asymptomatic HIV/, symptomatic HIV/, HOPES [27] Medical and demographic variables could not account for all of the variability of HRQL ratings. and AIDS patients (some with cancer) HIV/ patients with chronic diarrhea vs.
AIDS-HAQ [28]
Patients with diarrhea had worse declines in HRQL, especially in the areas of role functioning HIV/ patients without diarrhea and general health. They also accrued more medical care costs. Recurrent cytomegalovirus retinitis MOS HIV Survey, cytomegalovirus Combination therapy proved to be more effective for relapsed cytomegalovirus retinitis but at a (ganciclovir vs. foscarnet vs.
retinitis -specific HRQL instrument higher cost in terms of HRQL. combination therapy)
[29] Anemia associated with zidovudine Visual analogue scales for energy, All three aspects of HRQL improved for erythropoietin recipients whose hematocrit reached activities of daily living, and overall §38% without transfusion or discontinuation of zidovudine and who started with endogenous HRQL [30] erythropoietin levels of £500 IU/L. Disseminated M. avium complex infection Eastern Cooperative Oncology Group Patients whose blood culture for M. avium complex converted from positive to negative showed Functional Scale [31] improved performance overall. The Sickness Impact Profile (SIP) and the Symptom Distress Scale (SDS) have been used together in a study to validate recipients developed fewer opportunistic infections and had transient increases in CD4 cell counts, informally establishing their applicability in HIV disease (table 1) [16] . Both instruments showed similarly poor scores in psychosocial domains validity of KPS scores. This was most apparent in those patients whose CD4 cell count initially was õ100/mm 3 . However, there for AIDS and ARC patients. It was not in the power of either scale to distinguish between AIDS and ARC patients, and this was no difference in the therapeutic effects of AZT on HRQL for patients stratified by an initial diagnosis of AIDS study was not designed to assess the scales' ability to detect changes in clinical status over time. What is noteworthy, howvs. ARC. The effects of AZT toxicity on HRQL were not established. No information on interrater reliability of KPS ever, is that these scales were patient-rated, not physician-rated. Various versions of the Medical Outcomes Study (MOS) scores was given.
NOTE. AIDS-HAQ
The Quality of Well-Being (QWB) scale combines preferGeneral Health Survey, originally developed by the Rand Corporation (Santa Monica, CA), have been applied to HIVence-weighted measures of symptoms and functioning that are expressed on a continuum from death (0.0) to asymptomatic, infected patients. In 1991 Wu and colleagues formulated a short ''HIV-relevant,'' patient-rated, 30-item questionnaire from the optimum functioning (1.0). It includes elements of mobility, physical activity, and social activity and is therefore more comfunctional and overall well-being subscales of the MOS General Health Survey, called the MOS HIV Survey. They showed prehensive than the KPS scale. The QWB and KPS scales were used in a small study in the San Diego arm of the abovethat the MOS HIV Survey reliably distinguished between asymptomatic HIV-infected patients and those with early mentioned trial comparing AZT and placebo in AIDS and ARC patients (table 1) [13] . The mortality in the AZT group was symptomatic disease not categorized as having AIDS, in the areas of overall health, pain, physical function, role function, less than that in the placebo group in this study.
Because the QWB scale factors death into its score, the cognitive function, and overall quality of life (table 1) [17]. This was consistent with the findings of the SIP and SDS and QWB score was skewed in favor of the AZT group. However, the QWB scores showed trends similar to those in the KPS had the advantage of being less time-consuming for the patients to complete. Again, this study looked at patients at only one scores when data concerning those who died were removed, adding validity to the use of the QWB scale for HIV-infected point in time. Because the MOS HIV Survey was adapted from a generic, psychometric scale, the scores for HIV-infected patients. It should be noted that the QWB scale was administered by two trained interviewers who were blinded to treatment patients could be compared with those for patients with other chronic diseases (table 1) . groups. The KPS score was determined by one care provider, and no interrater reliability was established.
The [14] . This was successful in linking a more conventional measure of achieved by comparing the results from the MOS SF-20 to patients' reports of the presence of symptoms, their age and sex, HIV health status, the Walter Reed Classification, to a change in functional status score. While it was a small study and no mention non-white race, and intravenous drug use. Unlike the MOS HIV Survey, the MOS-SF 20 does not include the assessment of enwas made of who determined KPS scores, it indirectly validated the KPS scale for use with HIV-infected patients. ergy, cognitive function, or distress secondary to health problems. In 1993 the MOS HIV Survey was used to compare funcAs time went on, more formal attempts at validating HRQL scales for HIV disease were being made. Spitzer's Quality of tional status and well-being in a sample of patients from a placebo-controlled trial of high-dose AZT for early symptomLife Index (QLI) was examined for validity in measuring HRQL for HIV-infected patients by comparing it to several atic HIV disease (AIDS Clinical Trials Group [ACTG] Study 016) (table 1) [19] . It is of interest that at 12 weeks there were well-established measures of psychopathology and psychosocial and physical functioning, including the Social Supports no differences in any subscale tested between the AZT-treated group and the placebo group. At 24 weeks, there was a signifiScale and the Global Assessment of Functioning Scale (table 1) [15] . There was a highly significant correlation found becantly better HRQL measured in all areas of well-being for the placebo group, including overall health, energy, mental health, tween the support domain of the QLI and the Social Supports Scale. A significant correlation was found between the outlook health distress, and pain, but no differences were found in the functional subscales. At 52 weeks the AZT-treated and placebo domain and most measures of psychopathology, and a modest correlation between the activity domain of the QLI and a medigroups had similar scores overall. The magnitude of decline in HRQL scores due to treatment with AZT was similar to that cal staging scale and the Global Assessment of Functioning Scale. It was concluded that the five-item physician-rated scale of going from being asymptomatic to symptomatic in the previously mentioned study using the MOS HIV Survey. was valid for use in measuring HRQL, but its ability to distinguish between levels of severity of disease and progression of The Q-TWiST method was applied retrospectively to the same study patients in ACTG Study 016; however, data from disease was not established. . It covers the dimensions of life satisfaction, general health perception, physical functioning, related health states were defined and categorized as (1) the time from study entry until the occurrence of an adverse sympemotional well-being, fatigue, disability, pain, memory problems, and other symptoms. When examining the extent to which tomatic event or disease progression, (2) the period of time between the occurrence of the first severe, adverse symptomatic symptoms predict reported levels of functioning and how functioning and symptoms impact on overall health assessment and event and disease progression, and (3) the remaining survival time after disease progression. The final results were very similife satisfaction, Cleary et al. [24] found that each symptom from the symptom scale correlated with level of functioning, lar to those of the study using the MOS HIV Survey, showing a cost in terms of HRQL for treatment with AZT and thus but the best predictors of functioning were the summary physical-symptom score and the fatigue score. The instrument was validating those results. The Q-TWiST, however, is unable to identify which aspects of HRQL are more significantly affected administered face-to-face in this study. Later, a self-administered version of the instrument and the and is therefore less interpretable in terms of individual patients but is better suited for financial analyses.
MOS HIV Survey were compared to the Hospital Anxiety and Depression Scale score, the Centers for Disease Control and In 1994 the Q-TWiST method was utilized again to compare low-dose AZT (500 mg/d) and placebo for asymptomatic HIVPrevention (CDC) stage, and CD4 and CD8 cell counts of HIVinfected homosexual men, including asymptomatic patients, infected patients (table 1) [21] . The original study (ACTG Study 019) compared AZT at two different doses (500 mg/d and 1,500 symptomatic patients, and patients with the diagnosis of AIDS (table 1) [25]. This study confirmed the reliability and validity mg/d) to placebo in these patients. Progression-free survival at 18 months in the original study was 94% for low-dose AZT of the two scales in measuring HRQL for HIV-infected patients by comparing them to the Hospital Anxiety and Depression recipients and 89% for placebo recipients. Health states were defined similarly to those in the aforementioned study.
Scale. However, psychological and cognitive measures, including global ratings of HRQL, did not correlate with health indiThe two groups had approximately equal amounts of time before disease progression or an adverse symptomatic event, ces or CDC stage. Changes in HRQL in HIV-infected patients have also been and AZT recipients had more time after an adverse event than did the placebo group. Theoretical threshold utility analyses assessed over a 12-month period with use of a hybrid questionnaire, called the AIDS-HAQ, consisting predominantly of the were again constructed to define the limits of patient-ascribed utility weights that would produce optimal treatment planning.
Health Assessment Questionnaire with subscales from the MOS General Health Survey concerning mental health, cogniEven at lower doses, AZT was found to impinge on HRQL.
A modified Q-TWiST method was used by Revicki et al. in tion, energy, social functioning, and symptom scale (table 1) [26] . There was a striking loss of HRQL in symptomatic pa-1995 to assess the impact on HRQL associated with rifabutin prophylaxis for Mycobacterium avium complex (MAC) in patients, even if they did not have an AIDS-defining illness. Patients with AIDS also had a significant decline in HRQL, tients with AIDS (table 1) [22] . This was a secondary, retrospective analysis of two previously reported multicenter, raneven more than that for symptomatic patients without AIDS. Both groups had significant declines in all aspects of role domized, placebo-controlled clinical trials. Eighteen health states were defined with use of a combination of the Karnofsky functioning and had significantly high levels of disease symptoms, but they showed no significant decline in cognition or Index, symptoms of fever and night sweats, anemia, hospitalizations, and positive or negative blood cultures for MAC. mental health. Patients with AIDS and symptomatic HIVinfected patients also reported fewer hours at work and more Physicians were then asked to rate the health states by developing a utility score using the Health Utility Index (HUI), disability days than asymptomatic patients. These findings were consistent with those of other studies except that the AIDSwhich covers dimensions of sensory ability, mobility, emotional function, self-care, pain, and discomfort. Q-TWiST HAQ demonstrated worse HRQL for HIV-infected patients with AIDS than for those who were only symptomatic. scores with these measures and health states were significantly higher for patients who received rifabutin prophylaxis. It should More recently, the HIV Overview of Problems Evaluation System (HOPES) was developed [27] . In a cross-sectional be noted, however, that there was little accounting for adverse effects of rifabutin therapy in this study and that patient input study examining the relationship between clinical and biological factors and HRQL measured by the HOPES instrument, it was not utilized for assigning utility weights.
The Standard Gamble instrument has been shown not to was noted that medical and demographic variables explained only a portion (35%) of the variability of HRQL ratings for have the ability to discriminate between HIV disease states and shows no correlation with the MOS HIV Survey and other these patients ( The results revealed that patients with chronic diarrhea requirements for formal validation of HRQL instruments are becoming more stringent in order to make the process more had more severe declines in HRQL over 1 year than their counterparts in role functioning (social activity, daily living, scientific and accurate. Those instruments that have been formally validated -the MOS HIV Survey, the AIDS-HAQ, and energy, and cognition) and in the general health area. They also accrued higher costs for medical care and home health the QLI -show that for patients with (early) symptomatic HIV infection there is a significant impact on HRQL that is similar care services.
In a comparison of foscarnet, ganciclovir, and combination to that for those with AIDS (late-stage HIV infection). Specifically, there is little correlation between psychological scores therapy for relapsed cytomegalovirus (CMV) retinitis in a randomized, controlled clinical trial, combination therapy proved and disease stage or health indices. New and expensive combination therapies for HIV infection to be more effective in preventing the progression of CMV retinitis, yet the cost in terms of HRQL to the patient was that lengthen life but manifest serious side effects and impinge on daily living have made utilization of the measurement of significant (table 1) [29] . Both a visual-specific HRQL scale and the MOS HIV Survey were used in this study. In addition, HRQL imperative. Both the financial burden associated with these regimens and compliance issues also warrant investigamore patients were withdrawn from the combined-therapy arm of the study than from the monotherapy arms for reasons of tion of HRQL associated with them. Convincing data from the studies involving AZT and combination therapy for CMV toxic effects revealed by laboratory results.
Visual analogue scales for energy, activities of daily living, retinitis show that the benefits of effective treatments do not come without a price in terms of HRQL. This is valuable and overall quality of life were used in a randomized, doubleblind, placebo-controlled trial of treatment with recombinant information for the physician and patient for predicting the impact of new treatments on HRQL and determining optimal human erythropoietin (r-HuEPO) for anemia in patients with AIDS receiving AZT therapy [30] . The trial showed that all treatment regimens.
With new drug combinations for HIV and opportunistic inthree aspects of HRQL improved significantly for r-HuEPO recipients starting with endogenous erythropoietin levels of fections, there will likely always be an emphasis on utility analysis for financial and marketing purposes. However, this £500 IU/L whose hematocrit reached 38% or more without transfusion or discontinuation of AZT therapy. However, is not to say that patient-rated psychometric elements cannot be incorporated into these analyses. For example, use of the changes in HRQL were not analyzed for patients whose initial endogenous erythropoietin levels were ú500 IU/L and who modified Q-TWiST method by Revicki et al.
[22] to determine the effects of prophylaxis for MAC on HRQL was a more did not have a significant change in hematocrit. Therefore, the correlation between improvement in hematocrit and improvecompelling study than that using the Q-TWiST for AZT treatment of early HIV disease because health states in the former ment in HRQL could not be made definitively.
A retrospective study in 1994 examined the effects of MAC study were more specific and gauged by the HUI, which determines utility weights with psychometric properties. The chalbacteremia culture conversion on functioning, survival, and morbidity among patients with AIDS (table 1) [31] . The palenge in the future will be to allow patients to determine their own utility weights, such as HUI weights, in a meaningful, tients had previously enrolled in an open, multicenter HIV treatment study. The Eastern Cooperative Oncology Group interpretable way for health states. Some psychometric models, such as the AIDS-HAQ, include (ECOG) functional scale was used, and information was extracted from the patient's case record for scoring by a physician.
dimensions that focus on cost and drug toxicity. Whereas these psychometric measures are not always optimal in clinical trials The result was improved overall performance in those patients whose blood culture for MAC converted from positive to negainvolving new medications, they are excellent for comparing the specific HRQL manifestations of complications of HIV tive. The study was limited by the fact that HRQL scores were physician-assigned, the reliability of physician raters was not infection and opportunistic infections, such as chronic diarrhea, while also accounting for the financial burden and iatrogenic established, and no formal attempts at validation were made.
The HIV Patient-Reported Status and Experience Scale therapeutic toxicities of these phenomena. Finally, HRQL scales developed from generic psychometric (HIV-PARSE instrument) can also be found in the HIV literature [32] . It has already been used in several ACTGs.
instruments such as the MOS HIV Survey enable one to compare HRQL with HIV infection to that with other chronic diseases. This is an advantage that HIV-specific scales do not Discussion have. If these generic health profiles are used for specific opportunistic infections, it is probably best that they are used in Most of the initial studies concerning HRQL for HIVinfected patients focused on establishing the responsiveness, conjunction with a disease-specific or organ-specific instrument to ensure their sensitivity. reliability, and validity of existing and newly developed HRQL instruments for this population. The measurement of HRQL Future refinements of HRQL instruments should include improvement of discrimination across disease stages that allows for patients with HIV infection is still in evolution, as it is for patients with other diseases. The reader should be aware that for improved interpretability of scores. Whatever the future / 9c43$$ja26 11-24-97 20:09:05 cida UC: CID
